Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer.

Torino F, Barnabei A, De Vecchis L, Sini V, Schittulli F, Marchetti P, Corsello SM.

Crit Rev Oncol Hematol. 2014 Jan;89(1):27-42. doi: 10.1016/j.critrevonc.2013.07.007. Epub 2013 Aug 13. Review.

PMID:
23953684
2.

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.

Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci G, Lopez M.

Ann Oncol. 2012 May;23(5):1121-9. doi: 10.1093/annonc/mdr412. Epub 2011 Sep 28.

3.

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A.

Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4.

4.

Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women.

Bruno M, Digennaro M, Tommasi S, Stea B, Danese T, Schittulli F, Paradiso A.

Eur J Cancer Care (Engl). 2010 May;19(3):360-8. doi: 10.1111/j.1365-2354.2009.01067.x. Epub 2009 Nov 13.

PMID:
19912305
5.

Association between mode of breast cancer detection and diagnosis delay.

Crispo A, Montella M, Barba M, Schittulli F, De Marco MR, Grimaldi M, Quaranta M, Serravezza G, Savastano C, Botti G, La Vecchia C, D'Aiuto G.

Breast. 2009 Dec;18(6):382-6. doi: 10.1016/j.breast.2009.10.001. Epub 2009 Oct 30.

6.

BRCA1 expression and molecular alterations in familial breast cancer.

Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, Simone G, Schittulli F, Paradiso A.

Histol Histopathol. 2009 Jan;24(1):69-76. doi: 10.14670/HH-24.69.

PMID:
19012246
7.

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.

Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA.

Breast Cancer Res Treat. 2009 Jul;116(2):303-9. doi: 10.1007/s10549-008-0183-2. Epub 2008 Sep 23.

PMID:
18821012
8.

Molecular and in silico analysis of BRCA1 and BRCA2 variants.

Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A.

Mutat Res. 2008 Sep 26;644(1-2):64-70. doi: 10.1016/j.mrfmmm.2008.07.005. Epub 2008 Jul 18.

PMID:
18694767
9.

RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease.

Bellizzi A, Mangia A, Chiriatti A, Petroni S, Quaranta M, Schittulli F, Malfettone A, Cardone RA, Paradiso A, Reshkin SJ.

Int J Mol Med. 2008 Jul;22(1):25-31.

PMID:
18575772
10.

[Prevention and treatment of nausea and vomiting induced by chemotherapy. Introduction].

Schittulli F.

Tumori. 2008 Mar-Apr;94(2):suppl 1-5. Italian. No abstract available.

PMID:
18564619
11.

Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers.

Mangia A, Chiarappa P, Tommasi S, Chiriatti A, Petroni S, Schittulli F, Paradiso A.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):75-83. doi: 10.1016/j.cancergencyto.2008.01.002.

PMID:
18406868
12.

Disease family history and modification of breast cancer risk in common BRCA2 variants.

Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, Strada M, Morini N, Naldoni C, Paradiso A, Tommasi S, Schittulli F, Amadori D, Calistri D.

Oncol Rep. 2008 Mar;19(3):783-6.

PMID:
18288416
13.

MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.

Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E, Giannelli G.

Anticancer Res. 2007 Sep-Oct;27(5B):3593-600.

14.

Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.

Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC.

Breast Cancer Res. 2007;9(5):R59.

15.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Eur J Cancer. 2007 Jul;43(11):1679-86. Epub 2007 Jun 29.

PMID:
17601725
16.

655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.

Tommasi S, Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D, Scott G, Eppenberger-Castori S, Calistri D, Casadei S, Seymour I, Longo S, Giannelli G, Pilato B, Simone G, Benz CC, Paradiso A.

Cell Oncol. 2007;29(3):241-8.

17.

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A.

Int J Cancer. 2007 May 15;120(10):2078-85.

18.

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.

Tumori. 2006 Jul-Aug;92(4):311-7.

PMID:
17036522
19.

Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.

Benz CC, Fedele V, Xu F, Ylstra B, Ginzinger D, Yu M, Moore D, Hall RK, Wolff DJ, Disis ML, Eppenberger-Castori S, Eppenberger U, Schittulli F, Tommasi S, Paradiso A, Scott GK, Albertson DG.

Genes Chromosomes Cancer. 2006 Nov;45(11):983-94.

PMID:
16883574
20.

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VC, Zito AF, Specht K, Hoefler H, Golouh R, Schittulli F, Schmitt M, Beex LV, Klijn JG, Wang Y.

J Clin Oncol. 2006 Apr 10;24(11):1665-71. Epub 2006 Feb 27.

PMID:
16505412
21.

BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.

Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D, Mangia A, Paradiso A.

Mutat Res. 2005 Oct 15;578(1-2):395-405. Epub 2005 Jul 18.

PMID:
16026807
22.

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, Schittulli F, Lorusso V.

Ann Oncol. 2005 May;16 Suppl 4:iv14-19.

PMID:
15923415
23.

HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast.

Parrella P, Scintu M, Prencipe M, Poeta ML, Gallo AP, Rabitti C, Rinaldi M, Tommasi S, Paradiso A, Schittulli F, Valori VM, Toma S, Altomare V, Fazio VM.

Cancer Lett. 2005 May 10;222(1):75-81.

PMID:
15837543
24.

Reduction in the number of women with advanced breast cancer stage at diagnosis in Italy.

Montella M, Schittulli F.

Eur J Cancer Prev. 2005 Feb;14(1):79-80. No abstract available.

PMID:
15677900
25.

The impact of body mass index and type 2 diabetes on breast cancer: current therapeutic measures of prevention.

Resta F, Triggiani V, Sabbà C, Licchelli B, Ghiyasaldin S, Liso A, Schittulli F, Quaranta M, Paradiso A, Tafaro E, Guastamacchia E.

Curr Drug Targets Immune Endocr Metabol Disord. 2004 Dec;4(4):327-33.

PMID:
15578984
26.

Analysis of the reasons for accepting or declining participation in genetic research for breast cancer: a hospital-based population study.

Paradiso A, Bruno M, Cicoria O, Digennaro M, Longo S, Rinaldi M, Schittulli F.

Tumori. 2004 Jul-Aug;90(4):435-6.

PMID:
15510991
27.

Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.

Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM.

Clin Cancer Res. 2004 Aug 15;10(16):5349-54.

28.

Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population.

Bruno M, Tommasi S, Stea B, Quaranta M, Schittulli F, Mastropasqua A, Distante A, Di Paola L, Paradiso A.

Ann Oncol. 2004;15 Suppl 1:I48-I54.

PMID:
15280188
29.

Genetic alterations in hereditary breast cancer.

Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, Bruno M, Lombardi G, Schittulli F, Sensi E, Tancredi M, Bevilacqua G, Caligo MA.

Ann Oncol. 2004;15 Suppl 1:I7-I13.

PMID:
15280181
30.

MUC3 and MCA serum levels and steroid receptor content in breast cancer.

Quaranta M, Coviello M, Daniele A, Abbate I, Durrant LG, Paradiso A, Schittulli F.

Int J Biol Markers. 2004 Apr-Jun;19(2):109-14.

PMID:
15255542
31.

Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.

Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N, Schittulli F, Colucci G; Grupo Oncologico Italia Meridionale.

Semin Oncol. 2004 Apr;31(2 Suppl 5):13-9.

PMID:
15199527
32.

Prognostic relevance of histological grade and its components in node-negative breast cancer patients.

Volpi A, Bacci F, Paradiso A, Saragoni L, Scarpi E, Ricci M, Aldi M, Bianchi S, Muretto P, Nuzzo F, Simone G, Mangia A, Schittulli F, Amadori D.

Mod Pathol. 2004 Sep;17(9):1038-44.

33.

Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.

Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F, Grano M, Quaranta M, Antonaci S.

Int J Cancer. 2004 May 1;109(5):782-5.

34.

Prognostic relevance of mitotic activity in patients with node-negative breast cancer.

Medri L, Volpi A, Nanni O, Vecci AM, Mangia A, Schittulli F, Padovani F, Giunchi DC, Zito A, Amadori D, Paradiso A, Silvestrini R.

Mod Pathol. 2003 Nov;16(11):1067-75. Erratum in: Mod Pathol. 2004 Aug;17(8):1024. Vito, Alfredo [corrected to Zito, Alfredo].

35.

Ovarian fibroma: our experience of 34 cases.

Gargano G, De Lena M, Zito F, Fanizza G, Mattioli V, Schittulli F.

Eur J Gynaecol Oncol. 2003;24(5):429-32.

PMID:
14584663
36.

Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes.

Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A.

Clin Chem. 2003 Oct;49(10):1664-7. No abstract available.

37.

Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets.

Guastamacchia E, Resta F, Mangia A, Schittulli F, Ciampolillo A, Triggiani V, Licchelli B, Paradiso A, Sabbà C, Tafaro E.

Curr Drug Targets Immune Endocr Metabol Disord. 2003 Sep;3(3):205-9.

PMID:
12871027
38.

HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer.

Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A.

J Clin Oncol. 2003 Jul 15;21(14):2708-12.

PMID:
12860948
39.

Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.

Lorusso V, Crucitta E, Silvestris N, Catino A, Caporusso L, Mazzei A, Guida M, Latorre A, Sambiasi D, D'Amico C, Schittulli F, Calabrese P, De Lena M.

Br J Cancer. 2003 Feb 24;88(4):491-5.

40.

Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses.

Mangia A, Tommasi S, Reshkin SJ, Simone G, Stea B, Schittulli F, Paradiso A.

Oncol Rep. 2002 Sep-Oct;9(5):1127-32.

PMID:
12168084
41.

Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis.

Paradiso A, Ranieri G, Silvestris N, Naccarato G, Bevilacqua G, Mangia A, Leone B, Vallejo C, Simone G, Schittulli F, De Lena M.

Clin Exp Med. 2001 Sep;1(3):127-32.

PMID:
11833848
42.

Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.

Paradiso A, Schittulli F, Cellamare G, Mangia A, Marzullo F, Lorusso V, De Lena M.

J Clin Oncol. 2001 Oct 1;19(19):3929-37.

PMID:
11579113
43.

Predictability of monthly and yearly rhythms of breast cancer features.

Paradiso A, Serio G, Fanelli M, Mangia A, Cellamare G, Schittulli F.

Breast Cancer Res Treat. 2001 May;67(1):41-9.

PMID:
11518465
44.

GnRH receptors in human breast cancer and its contiguous not-involved breast tissue.

Paradiso A, Pezzetta A, Cellamare G, Schittulli F, Marzullo F, Reshkin SJ.

J Endocrinol Invest. 2000 Feb;23(2):90-6.

PMID:
10800761
45.

Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients.

Paradiso A, Tommasi S, Barletta A, Leone B, Lacava J, Vellejo C, Labriola A, Marzullo F, Altieri R, Schittulli F, De Lena M.

Anticancer Res. 1999 Sep-Oct;19(5C):4523-8.

PMID:
10650804
46.

Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome.

Mangia A, De Lena M, Barletta A, Marzullo F, Attolico M, Stea B, Petroni S, Labriola A, Cellamare G, Digiesi G, Altieri R, Schittulli F, Paradiso A.

J Exp Clin Cancer Res. 1998 Sep;17(3):317-23.

PMID:
9894769
47.

Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: a pilot study.

Lorusso V, Catino A, Schittulli F, Longo S, Racanelli A, Timurian A, Marzullo F, Simone G, Brandi M, De Lena M.

Int J Oncol. 1998 May;12(5):1177-81.

PMID:
9538146
48.

Comparison of formalin, ethanol, and Histochoice fixation on the PCR amplification from paraffin-embedded breast cancer tissue.

Giannella C, Zito FA, Colonna F, Paradiso A, Marzullo F, Alaibac M, Schittulli F.

Eur J Clin Chem Clin Biochem. 1997 Aug;35(8):633-5.

PMID:
9298355
49.

Analysis of clonal antigen receptor gene rearrangements in T-cells involved with Kaposi's sarcoma.

Alaibac M, Congedo M, Barbarossa G, Bottiglieri A, Fillippi ED, Marzullo F, Quarta G, Schittulli F.

Anticancer Res. 1997 Mar-Apr;17(2A):1205-7.

PMID:
9137472
50.

Cytokeratins and proliferation in breast cancer patients.

Correale M, Reshkin S, Tedone T, Abbate I, Mangia A, Schittulli F, Paradiso A.

Int J Oncol. 1996 Nov;9(5):1007-12.

PMID:
21541608

Supplemental Content

Loading ...
Support Center